Search research articles
Contact Us
Filters
Showing results (81-90 of 138) with videos related to
Page
of 14
Sort By:
Cancers
|
May 11, 2024
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation
Luca Potestio, Massimiliano Scalvenzi, Aimilios Lallas, et al.
The Journal of Dermatological Treatment
|
July 13, 2022
Dupilumab for the treatment of adult atopic dermatitis in special populations
Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, et al.
Expert Opinion on Drug Safety
|
August 23, 2025
Efficacy and tolerability of bimekizumab within patients with moderate-to-severe plaque psoriasis: learnings from real world evidence
Matteo Megna, Daniele Cecere, Michela D'Agostino, et al.
Dermatologic Therapy
|
May 15, 2022
A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis
Maddalena Napolitano, Gabriella Fabbrocini, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology
|
March 26, 2024
The Past, the Present and the Future of Teledermatology: A Narrative Review
Nello Tommasino, Matteo Megna, Sara Cacciapuoti, et al.
Biomedicines
|
August 26, 2023
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
Luca Potestio, Teresa Battista, Sara Cacciapuoti, et al.
Clinical, Cosmetic and Investigational Dermatology
|
October 2, 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Expert Opinion on Drug Safety
|
September 28, 2023
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation
Luca Potestio, Elisa Camela, Sara Cacciapuoti, et al.
The Journal of Dermatological Treatment
|
May 23, 2022
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
Matteo Megna, Nello Tommasino, Luca Potestio, et al.
Italian Journal of Dermatology and Venereology
|
July 23, 2024
ChatGPT and dermatology
Michela D'Agostino, Federica Feo, Fabrizio Martora, et al.
Page
of 14
Search research articles
Search
Showing results (81-90 of 138) with videos related to
Sort By:
Page
of 14
Cancers
|
May 11, 2024
Efficacy and Safety of Cemiplimab for the Management of Non-Melanoma Skin Cancer: A Drug Safety Evaluation
Luca Potestio, Massimiliano Scalvenzi, Aimilios Lallas, et al.
The Journal of Dermatological Treatment
|
July 13, 2022
Dupilumab for the treatment of adult atopic dermatitis in special populations
Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, et al.
Expert Opinion on Drug Safety
|
August 23, 2025
Efficacy and tolerability of bimekizumab within patients with moderate-to-severe plaque psoriasis: learnings from real world evidence
Matteo Megna, Daniele Cecere, Michela D'Agostino, et al.
Dermatologic Therapy
|
May 15, 2022
A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis
Maddalena Napolitano, Gabriella Fabbrocini, Luca Potestio, et al.
Clinical, Cosmetic and Investigational Dermatology
|
March 26, 2024
The Past, the Present and the Future of Teledermatology: A Narrative Review
Nello Tommasino, Matteo Megna, Sara Cacciapuoti, et al.
Biomedicines
|
August 26, 2023
New Onset and Exacerbation of Psoriasis Following COVID-19 Vaccination: A Review of the Current Knowledge
Luca Potestio, Teresa Battista, Sara Cacciapuoti, et al.
Clinical, Cosmetic and Investigational Dermatology
|
October 2, 2023
Effectiveness of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis Located in Difficult-to-Treat Areas
Sara Cacciapuoti, Luca Potestio, Gianluca Guerrasio, et al.
Expert Opinion on Drug Safety
|
September 28, 2023
Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation
Luca Potestio, Elisa Camela, Sara Cacciapuoti, et al.
The Journal of Dermatological Treatment
|
May 23, 2022
Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
Matteo Megna, Nello Tommasino, Luca Potestio, et al.
Italian Journal of Dermatology and Venereology
|
July 23, 2024
ChatGPT and dermatology
Michela D'Agostino, Federica Feo, Fabrizio Martora, et al.
Page
of 14